Mirvetuximab Soravtansine
Fallopian Tube
University of Alabama at Birminghamantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Fallopian Tube cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Enzalutamide Memorial Sloan Kettering Cancer Center | Phase 2 | B |
Nivolumab Memorial Sloan Kettering Cancer Center | Phase 1 | CCC |
Ny-Eso-1 Vaccine Memorial Sloan Kettering Cancer Center | Phase 1 | CC |
Abt-767 AbbVie (prior sponsor, Abbott) | Phase 1 | CC |
Carboplatin Memorial Sloan Kettering Cancer Center | Phase 1 | CC |
wt1 vaccine Memorial Sloan Kettering Cancer Center | Phase 1 | CC |
Ipilimumab Memorial Sloan Kettering Cancer Center | Phase 1 | CC |
Same molecule, other indications
Mirvetuximab Soravtansine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →